Company Filing History:
Years Active: 2007
Title: The Innovations of Andreas Bueltmann: Pioneering Heart Failure Solutions
Introduction
Andreas Bueltmann is a distinguished inventor based in Munich, Germany, known for his significant contributions to the field of heart health. With one patent to his credit, he is making strides in advancing medical research and treatment options for heart failure. His innovative work is vital for developing effective therapies to address cardiovascular diseases.
Latest Patents
His patent, titled "Use of EDG2 receptor in an animal model of heart failure," focuses on utilizing G protein-coupled receptor EDG2 in mammalian myocardial cells. This groundbreaking approach offers insights into the mechanisms of heart failure and opens new avenues for therapeutic interventions in animal models, showcasing Bueltmann’s commitment to improving heart health.
Career Highlights
Andreas Bueltmann is currently affiliated with Sanofi-Aventis Deutschland GmbH, where he leverages his expertise in pharmacology and biomedical research. Over the years, he has been instrumental in various research initiatives aimed at developing innovative treatments that benefit patients suffering from heart-related conditions.
Collaborations
Throughout his career, Bueltmann has collaborated with key professionals in the field, including Evi Kostenis and Paulus Wohlfart. These partnerships have enabled cross-disciplinary efforts that enhance the research and development processes, leading to advancements in cardiovascular therapeutics.
Conclusion
In summary, Andreas Bueltmann represents the innovative spirit of the medical research community. His patent on the EDG2 receptor and his collaborations with esteemed colleagues position him as a forward-thinking inventor in the realm of heart disease solutions. His work not only impacts the scientific community but also brings hope to countless individuals affected by heart failure.